Using Lab-Grown Retinas, Researchers Take Steps Toward Curing ColorblindnessAllbiopro2018-10-13T13:46:55+09:0010월 13th, 2018|
Bay State Life Sciences Companies Offer Strong Incentives Packages to Woo New HiresAllbiopro2018-10-13T13:46:28+09:0010월 13th, 2018|
After FDA Advisory Committee Rejection, Trevena Now Faces a Class Action LawsuitAllbiopro2018-10-13T13:45:41+09:0010월 13th, 2018|
Chinese Pharma Companies Continue to Shake Hands With Western PartnersAllbiopro2018-10-13T13:45:15+09:0010월 13th, 2018|
How to Reach Your Goals at Work Despite Negative NancyAllbiopro2018-10-13T13:44:48+09:0010월 13th, 2018|
Pfizer, J&J, Amgen and Roche Start a Bare-Knuckle Brawl Over BiosimilarsAllbiopro2018-10-13T13:44:23+09:0010월 13th, 2018|
HHS Secretary Azar for attorney general? He’s not interested: WSJAllbiopro2018-10-13T13:43:57+09:0010월 13th, 2018|
FiercePharmaAsia—China cancer drug discounts; Celltrion’s Rituxan biosim; Otsuka-Proteus digital pill dealAllbiopro2018-10-13T13:43:30+09:0010월 13th, 2018|
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?Allbiopro2018-10-13T13:43:03+09:0010월 13th, 2018|
Johnson & Johnson one-ups Eliquis as Xarelto nabs $1.5B FDA nod in artery diseaseAllbiopro2018-10-13T13:42:35+09:0010월 13th, 2018|
AbbVie inks yet another Humira biosim deal—this time with Novartis—as EU launches nearAllbiopro2018-10-13T13:42:09+09:0010월 13th, 2018|
Chutes & Ladders—DFCI’s Nick Haining to become VP of oncology at MerckAllbiopro2018-10-13T13:41:42+09:0010월 13th, 2018|
Adynxx merges with Alliqua, snagging Nasdaq listing ahead of pain trialsAllbiopro2018-10-13T13:41:15+09:0010월 13th, 2018|
Genmab on CMO use: ‘Keep brains inhouse, hands outside’Allbiopro2018-10-13T13:40:24+09:0010월 13th, 2018|
Biosimilar round-up: Deal-breaking, approvals, and patentsAllbiopro2018-10-13T13:39:58+09:0010월 13th, 2018|
Link between Gut Flora and Multiple Sclerosis DiscoveredAllbiopro2018-10-13T13:39:08+09:0010월 13th, 2018|
